Signet plans to offer assays to investigators conducting research into the detection and management of acute and chronic diseases.
Acute inflammation can result from sepsis, meningitis, respiratory infection, urinary tract infection, viral infection, and bacterial infection.
Chronic inflammation is often associated with diabetes mellitus, acute myocardial infarction, coronary artery disease, kidney diseases, and certain auto-immune disorders, such as rheumatoid arthritis and organ failure.
“The trypsin inhibitors Uri and Bik are cutting-edge biomarkers that can have a great impact on the diagnosis and management of diseases for inflammation, such as kidney disease,” said Dr Michael Pugia, director of Urinalysis R&D, Bayer Diagnostics. “We are confident that with Signet’s expertise in developing important immunoassays for medical researchers, these markers will one day improve and manage health in people affected by inflammatory diseases.”